OBJECTIVE： To evaluate clinical efficacy of Shenling baizhu powder combined with aminosalicylic acid in the treatment of ulcerative colitis （UC）， and to provide evidence-based reference in clinic. METHODS： Retrieved from PubMed， Cochrane library， CJFD， VIP， Wanfang database and CBM， randomized controlled trials （RCTs） about Shenling baizhu powder combined with aminosalicylic acid preparations （trial group） vs. aminosalicylic acid preparations alone （control group） in the treatment of UC were collected. Meta-analysis was performed by using Rev Man 5.2 statistical software after data extraction and quality evaluation with Cochrane systematic evaluator manual 5.1.0. RESULTS： A total of 14 RCTs were included， involving 1 177 patients. Meta-analysis showed that total response rate of trial group was significantly higher than that of control group [OR＝3.40， 95％CI（2.44，4.74），P＜0.001]， while Sutherland DAI score [MD＝－1.31，95％CI（－2.07，－0.56），P＜0.001]， the levels of TNF-α [SMD＝－1.90，95％CI（－2.90，－0.90），P＜0.001]， IL-17[MD＝－85.18，95％CI（－100.51，－69.85），P＜0.001] and IL-23 [MD＝－113.27，95％CI（－132.34，－94.21），P＜0.001] in trial groups were significantly lower than control group， with statistical significance. CONCLUSIONS： Therapeutic efficacy of Shenling baizhu powder combined with aminosalicylic acid preparation is better than aminosalicylic acid preparation alone in the treatment of UC， and can significantly reduce Sutherland DAI and the levels of serum cytokines.